Ziltivekimab fails to reduce cardiovascular events in ZEUS clinical trial

The phase 3 ZEUS clinical trial found that the drug ziltivekimab did not reduce rates of heart attack, stroke, or cardiovascular death compared to a placebo.

Ziltivekimab fails to reduce cardiovascular events in ZEUS clinical trial
Photo: Medical Xpress

The phase 3 ZEUS clinical trial found that the drug ziltivekimab did not reduce rates of heart attack, stroke, or cardiovascular death compared to a placebo. In the study, the primary endpoint occurred in 561 participants in the treatment group and 565 in the placebo group. While the drug lowered interleukin-6 (IL-6) levels, it did not reduce cardiovascular event rates.

The trial was led by Mass General Brigham researcher Paul Ridker, M.D. Participants in ZEUS had atherosclerotic cardiovascular disease and systemic inflammation. Unlike the previous CANTOS trial, ZEUS participants were a decade older and often had longstanding diabetes, heart failure, and significant kidney disease.

Paul Ridker said the findings illustrate that science is often about trial and error and that researchers do not yet have all the answers. He noted that one logical next step is to move upstream to find the right target, such as the NLRP3 inflammasome. Ridker also suggested that IL-6 inhibition might be effective if it had targeted a different patient population.

Safety results were reassuring with no adverse effect on total mortality, though researchers observed a small increase in infection rates. For patients with stable atherosclerotic disease, the low-dose drug colchicine has already been shown to significantly reduce cardiovascular event risks.

Key facts

  • The primary endpoint occurred in 561 treatment group participants and 565 placebo group participants.
  • ZEUS participants were older and had more comorbidities, such as kidney disease and diabetes, than those in the CANTOS trial.

Perspectives

Neutral

The ZEUS trial showed that ziltivekimab lowered IL-6 levels but did not result in a statistically significant reduction in cardiovascular events.

Negative

The trial observed a small increase in rates of infection among participants.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Next storyResearchers use pink noise to increase brain waste clearance during sleep

All sections

Edition